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Comparative genomic hybridization (CGH) analysis of DNA extracted from a diffuse lymphoma with a large cell component (DLLC) that displayed double minute chromosomes upon conventional karyotypic analysis indicated overt amplification of DNA sequences derived from the 2p13-15 region. Southern blot analysis of this tumor DNA with a cDNA probe for the proto-oncogene R f f , previously mapped t o 2p14-15, indicated a greater than 35-fold amplification of REL. To determine the incidence of REL amplification and possible clinical or histologic association with DLLC, a panel of 11 1 tumor DNAs from DLLC specimens was screened for REL amplification by Southern blot analysis. A copy number of 2 4 was noted in 26 cases (23%). Southern blot analysis of these 26 tumor DNAs with a cDNA probe for TGFA, mapped t o 2p13, indicated lack of coamplification except in one case. Another member of the Rel/NF-KB family of IFFUSE LYMPHOMAS with a large cell component (DLLC), comprising diffuse large, small, mixed cell, and immunoblastic types makes up approximately 50% of Bcell non-Hodgkin's lymphoma (NHL,).' Despite the availability of potentially curative therapies, a significant proportion of DLLC patients relapse and succumb to recurrent The genetic basis of this biologic and clinical heterogeneity of DLLC is poorly understood. Recurring genetic abnormalities that define subsets of DLLC so far identified consist of four translocations that activate cellular proto-oncogenes: t(8; 14)(q24;q32) (MYC), t( IO; 14)(q24;q32) (NFKBZ), t(14; 18)(q32;q21) (BCL2), and t(3;14)(q27;q32) (BCL6): Although these transforming genetic lesions have been well studied, much less is known about progression-associated alterations in DLLC. In several tumor systems, a correlation between specific gene amplification and prognosis has been well documented.' Overt gene amplification in DLLC, detected cytogenetically by the presence of homogeneously staining regions (hsrs) and double minute chromosomes (dmins), has been reported infrequently.6.' Sporadic reports of specific gene amplification have also been documented,839 and in the latter study, REL was shown to be amplified in two follicular large cell lymphomas. Overall, very little is known about the incidence and biologic or clinical relevance of gene amplification in DLLC. The comparative genomic hybridization (CGH) technique enables identification of overrepresented and underrepresented DNA sequences in tumors and can be applied to specimens otherwise not amenable for analysis by traditional cytogenetic techniques.'0"2 Our CGH analysis of one DLLC tumor that exhibited dmins displayed a high level of amplification of DNA sequences derived from the 2~13-15 region. The REL proto-oncogene, previously mapped to this region (2p14-15),I3 was found to be amplified in the tumor DNA by Southern blot analysis. Subsequent assaying of a panel of DLLC DNA specimens showed that REL is frequently amplified in extranodal DLLC. transcriptional activators, RELAIp65 mapped t o 11q13, was amplified in five cases as determined by Southern blot analysis using a cDNA probe. Nineteen of the 26 DLLC (73%) with REL amplification were primary extranodal lymphomas. As a group, the tumors with REL amplification demonstrated an increased frequency of chromosomal aberrations previously associated with tumor progression, suggesting an oncogenic effect of amplified REL in B-lymphoid cells that already contained a transforming genetic lesion. Thus, REL amplification is a frequent event in DLLC, and probably constitutes a progression-associated marker of primary extranodal lymphomas. This study shows the usefulness of the CGH technique in identifying chromosomal regions overrepresented in tumors that can point t o amplified genes and may be correlated with clinical features of the disease. 0 1996 by The American Society of Hematology.
MATERIALS AND METHODS
Tumor specimens and cytogenetic analysis. During the period of January 1984 to December 1994, 495 DLLC specimens ascertained at the Memorial Sloan-Kettering Cancer Center were subjected to karyotype analysis. The specimens were divided for histologic classification according to the International Working Formulation, cytogenetic analysis, and snap-freezing for DNA extraction as previously described by us.14 Site of tumor presentation was evaluated by clinical and radiographic staging as previously des~ribed.'~ For the purposes of this analysis, tumors with primary presentation in lymph nodes or spleen were considered as primary nodal lymphomas.I6 Two tumors presenting as peripancreatic masses were considered primary nodal lymphomas because extranodal invasion could not be excluded. A subset of this ascertainment comprising 94 DLLC tumors at diagnosis and 17 DLLC tumors at relapse was used in the present investigation.
Comparative genomic hybridization (CGH). Tumor DNA was extracted from frozen tissue and subjected to CGH analysis essentially as described." Briefly, the tumor (test) DNA and normal (reference) DNAs were labeled by nick-translation with Fluorescein-12-dUTP and Texas Red-5-dUTP (NEN-DuPont, Boston, MA), respectively. Equal amounts (200 ng) of tumor and normal DNAs were coprecipitated with 10 pg of human Cot-l DNA (GIBCOBRL, Gaithersburg, MD) and resuspended in hybridization mix before in situ hybridization to human metaphase chromosome spreads prepared from phytohemagglutinin (Pm)-stimulated lymphocytes from normal individuals. After hybridization, the slides were washed and the chromosomes counterstained with 4,6-diamino-2-phenylindole (DAPI) to permit identification of the chromosomes. Fluorescent hybridization signals and DAPI-staining patterns were captured with a cooled charge-coupled device (CCD) camera (Photometrics, Tuscon, AZ) attached to a Nikon Microphot-SA microscope and processed using an image analysis system (Smart Capture Imaging; Digital Scientific, Cambridge, UK). The software performed a calculation of the green (tumor DNA) to red (normal DNA) fluorescent ratios along the length of each chromosome. The average of readings from eight chromosomes were graphed for each chromosome and compared with the profile for the same chromosome in a reference DNAheference DNA hybridization to set the boundaries of gain and loss. Ratios above 1.25 and below 0.85 were considered to represent chromosomal gain and loss, respectively.
Southern blot analysis and determination of gene copy number. Ten micrograms of each tumor DNA extracted from snap-frozen tissue was digested with the appropriate restriction enzyme, electrophoresed, transferred, and hybridized as described previously." The filters were sequentially hybridized with the cDNA probes REL, mapped to 2p14-15 (gift of Riccardo Dalla-Favera, Columbia University); KIT, mapped to 4qll-q22 (purchased from American Type Culture Collection [ATCC]); RELAIp65, mapped to I lq13 (gift of Jerry Z. Gong, Columbia University); and TGFA, mapped to 2p13 (gift of Ethan Dmitrovsky, Memorial Sloan-Kettering Cancer Center); and the polymorphic genomic probe D2S48, mapped to 2p21-23 (purchased from ATCC). The hybridization signals were quantitated using a Betascope (Betagen). REL hybridizations were performed twice for each tumor and the signals from the two experiments were averaged. The copy number of REL relative to a probe on the same chromosomal arm in each tumor specimen was calculated as a ratio of a normalized REL hybridization signal (tumor/placenta) to a normalized D2S48 signal (tumor/placenta). The copy number of REL also was calculated relative to the normalized hybridization signal (tumor/placenta) of KIT, as an arbitrary probe. Copy numbers of TGFA and RELA were calculated relative to D2S48. A copy number of two for each gene was taken as reference (diploid). A copy number of 2 4 for REL relative to KIT was considered to indicate amplification since polysomy 2 was infrequent in our ascertainment of NHL. Trisomy 2 was observed in 20 of 684 clonally abnormal NHL specimens from 645 patients, among which only four were DLLC cases (unpublished observations). Tetrasomy or higher aneuploid numbers of chromosome 2 were not encountered. A copy number of REL 2 4 relative to D2S48 also was considered to be indicative of regional amplification. The biopsy samples used in this study were comprised predominantly of tumor as determined by histologic examination. However, infiltrating lymphocytes and other normal cells were common. These normal cells can be expected to have a dilutional effect on signal levels from amplified genes in Southern blot analysis leading to an overall underestimation of REL amplification by this assay. Since CGH analysis of tumor IS99 showed a high level of gain of the 2~1 3 -I S region, a candidate gene approach was taken to identify the gene(s) amplified. One obvious candidate was REL, previously mapped to this region.'.' By Southern blot analysis of tumor 1599 DNA. the copy number of REL was determined to be 72 relative to a probe (D2S4X) mapped telomeric to REL at 2~2 1 -2 3 (Fig 3A) . This indicated that REL is contained within the amplicon derived from 2pl3-IS in tumor 1599. However. another probe (TGFA) mapped to 2p13 was not coamplified by Southern blot analysis of this tumor (Fig 3A) .
RESULTS

CGH unalysis.
Based on the above result. detailed Southern blot analysis of REL amplification was performed on a panel of DNAs from 1 I 1 histologically confirmed DLLC biopsy samples (including tumor 1599). Of these. 94 specimens were obtained at the time of diagnosis and 17 at relapse. Among the 1 1 1 cases, 79 were karyotypically abnormal and the remaining had either normal karyotypes or were cytogenetic failures. The tumor DNAs were hybridized sequentially with the REL and control probes (D2S4X and KIT). Copy numbers were calculated relative to both probes: however, the copy numbers of REL relative to D2S48 were not significantly different from those relative to KIT ( P > .9). In this panel of tumors, REL was found to be in 2 4 copy number in 26 cases (239): 4 copies in 8 cases. S copies in 12 cases, 7 copies in 2 cases. and 12, 16, 72, and 141 copies in 1 case each, respectively. As pointed out previously, these copy numbers. on the whole. probably represent an underestimation. No rearrangements of the REL gene were observed with the probe used. Higher copy numbers of TGFA (6 and 7) were detected in 3 cases (of 105). and in only 1 of these (tumor 150) was REL also amplified. In this tumor specimen, the copy numbers of REL and TGFA were I6 and 7, respectively. indicating a large initial amplification unit that subsequently decreased in size upon further amplification, possibly similar in size to that for tumor 1599. Because REL belongs to a family of proteins involved in transcriptional activation.Ix Southern blot analysis was performed with a probe for ;I related gene. RELA mapped to 1 Iq 13. A representative hybridization signal for this probe is shown in Fig 3B. with the corresponding D2S4X hybridization signal. In this panel of I 1 I DLLCs. two cases had four copies of RELA. whereas one case each had 6. 7, and 8 copies. respectively.
Clirlic,o-l,crtholo~ic crrltl c:\toCyeneric assc)c.itrtiorls. Of the 26 cases with 2 4 copies of REL. 23 were sampled at diagnosis and 3 at relapse of disease. In comparison. of the X5 cases with less than 4 copies of REL. 71 werc sampled at diagnosis and 14 at relapse ( P > .OS). Of the 26 cases with 2 4 copies of REL, 16 were male and IO female. There was no difference in the median age among DLLC with or without REL amplification. As shown in Table 1 . there was a tendency for extranodal involvement among the DLLC with REL amplification. Only 2 of 26 DLLC with REI, amplification had a primary site of presentation in lymph nodes. compared to 43 of 85 DLLC without REL amplification ( P < .01). Overall. 19 of 26 tumors with REL amplification were classified as primary extranodal lymphomas, compared to 39 of 85 DLLC without REL amplification ( P < .OS). There was a tendency for gastrointestinal tract involvement among the DLLC with REL amplification: a third of the cases presented as primary gastric or gastrointestinal tract lymphomas.
Of the 1 1 1 specimens assayed in this study, 79 exhibited karyotypic abnormalities, of which 20 also exhibited REL amplification by Southern blotting. Of these, 12 (60%) had either structural aberrations of 6q, 17p, or +7, -17. compared to I8 of the S9 (3 1%) DLLC without REL arnplifica- For personal at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From tion ( P < .05). Among 15 cases in this ascertainment that had a t(14; 18),t(3; 14), t(8; 14), or t(l1; 14), 3 (20%) showed REL amplification; this is compared to 64 cases without these translocations, of which 17 (27%) showed amplification of REL ( P > .05). There was no difference in the proportion of DLLC cases with t(3q27), +3 or structural abnormalities affecting chromosome 2, with or without REL amplification.
DISCUSSION
Very little is known about the involvement of gene amplification in the etiology and progression of DLLC. In tumors, karyotypic evidence for overt gene amplification presents as hsrs and dmins. Overrepresentation of large regions at low copy number evident as isochromosomes, whole chromosome gains, aberrantly banded markers, and unidentified markers also signify increased gene copies. For DLLC, only rare cases have been reported that display evidence for gene amplification by cytogenetic analy~is.~.' Specific gene amplification has also been noted in a limited number of cases, for a restricted set of gene probes.'.' Limitations of both cytogenetic and molecular assays for identification of amplification are obvious as reviewed recently.",12 Therefore, we reasoned that application of the CGH assay to DNA extracted from DLLC specimens which showed cytogenetic evidence of overt gene amplification (eg, hsrs, dmins) should provide clues to the identification of amplified genes. This molecular-cytogenetic assay has been previously successful in identifying the chromosomal derivation of DNA sequences amplified in a variety of tumor types, which in some cases were confirmed by in situ hybridization using appropriate painting and in other cases by Southern blot analysis using specific DNA probes." Novel amplified regions have also been revealed, directing subsequent studies for the isolation of the respective gene(s)." In a recent study on prostate cancer, CGH performed on recurrent, hormone-refractory tumors indicated amplification of DNA sequences derived from Xq 1 1 -13, and a mapped candidate, the androgen receptor (AR) gene, was found to be amplified in 30% of the tumors, and correlated with androgen deprivation therapy.22 In this study, application of CGH to DNA extracted from one DLLC that displayed dmins, indicated overt amplification of genetic material from 2~13-15. A candidate gene, REL, was found to be amplified by Southern blot analysis at least 35-fold, without the coamplification of TGFA, a gene mapped to the same region. The precise size of the amplicon is unknown and it is feasible that other genes are coamplified. Expression studies would confirm the identity of the driver gene.
In a follow-up study of a panel of DLLC, REL was noted to be amplified in 23% of cases without evidence for genomic rearrangements. A previous report described amplification of REL in 2 follicular large cell lymphomas and rearrangement in 1 DLLC, out of 7 cases that were selected for karyotypic abnormalities affecting the 2~11. 2-l4 region? In the panel of 1 I 1 tumors in this study, 2 (178 and 1527) displayed abnormalities in this region of chromosome 2, and neither exhibited amplification or rearrangement of REL. The frequent occurrence of REL amplification in extranodal lymphomas noted in this series constitutes one of the most frequent genetic aberrations associated with this clinical subset. Previous studies of extranodal lymphomas did not identify a common recurring genetic a b n~r m a l i t y .~~.~~ In a recent serially ascertained cohort of DLLC rearrangement of BCL6 was associated with extranodal involvement in the majority of cases.?' The association of extranodal DLLC and REL amplification detected in the current series appeared to be independent of co-incident translocations involving the sites of MYC, BCLI, BCL2, or BCL6 genes. On the other hand, REL amplification was significantly associated with deletions of 6q, trisomy 7, and monosomy 17 or deletions of 17p, all of which have been shown to be characteristic of later stages of lymphoma evolution.'' REL belongs to the Rel/NF-KB family of transcriptional activators that can heterodimerize and actively participate in cytoplasmic/nuclear signal transduction in response to cytokines, mitogens, physical and oxidative stress, and other pathogenic products.26 To date, five members of the ReVNF-KB gene family have been identified which include REL, RELA, RELB, NFKBI, and NFKB2. Heterodimers of these subunits bind DNA with distinct sequence specificity and transactivate transcription of a variety of genes.?' The various RelNF-KB complexes that form as well as the genes that they activate, have been reported to be cell type-and stagespecific.27 Re1 and NF-~Bl/p50 or p105 exhibit constitutive and inducible complexes in mature murine B cells, whereas RelA/p65 and NF-KBI are predominant in pre-B and non-B cells.'* The DNA binding activities of the heterodimers are regulated by a family of cytoplasmic inhibitors (IKB) that prevent translocation of the complexes to the nucleus.'* Four members of the ReVNF-KB family of genes have been implicated in oncogenesis. In DLLC, a t(10;14)(q24;q32) translocation has been shown to result in the activation of a NFKB2-IGH fusion gene," whereas in chronic lymphocytic leukemia, a t(14; 19)(q32;q13.1) translocation resulted in the overexpression of the BCLJ gene which encodes an IKBlike protein.3" A splice variant of RELA (p65A) has been shown to cause transformation of rat embryo fibroblasts3' and v-Rel, a truncated form of Re1 encoded from a transforming and replication-defective retrovirus (REV-T), causes rapid and lethal tumors in infected chickens.'? Recent data also suggest that sufficient overexpression of Re1 itself can cause transformation in some cell^^'.'^ and apoptosis in other^.'^ Our data on DLLC presented here suggest that in a B-lymphoid cell which already contains a transforming genetic lesion such as activation of MYC, BCLI, BCL2, BCL3, or BCM gene brought about by chromosome translocation, amplification of REL may result in inappropriate expression effecting constitutive activation of specific genes leading to tumor progression. It is interesting that only in five cases was RELA found to be in higher copy number, possibly reflecting the cell specificity of RELA described above.*' Amplification of REL is a frequent event in DLLC and its biologic role in the progression of a subset of these tumors that arise in extranodal sites is obviously important and remains to be elucidated. use only.
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